可成药基因组孟德尔随机化识别COVID-19药物重定位机会
研究基于转录组与蛋白组数据为1263个可成药蛋白构建遗传工具,采用孟德尔随机化分析7,554例COVID-19住院患者与逾百万对照,发现ACE2、IFNAR2、IL-10RB三个蛋白与住院风险显著相关,其中IFNAR2证据最强,提示应优先试验靶向IFNAR2和ACE2的药物用于COVID-19早期管理。
要点
- ACE2、IFNAR2、IL-10RB与COVID-19住院风险存在显著孟德尔随机化关联
- IFNAR2在共定位与通路分析中证据最强,最可能参与住院风险
- 建议优先开展靶向IFNAR2和ACE2药物的临床试验用于早期管理
核心结论
- ACE2、IFNAR2和IL-10RB为COVID-19住院的潜在治疗靶点
- IFNAR2较IL-10RB更可能参与COVID-19住院
- 应优先试验靶向IFNAR2和ACE2的药物用于COVID-19早期管理
研究设计与样本
- 采用孟德尔随机化分析,基于转录组与蛋白组数据为1263个可成药蛋白构建遗传工具
- 使用Host Genetics Initiative与Million Veteran Program汇总统计
- 纳入7,554例COVID-19住院患者与逾百万对照
主要发现
- ACE2与COVID-19住院显著相关,P = 1.6 × 10-6
- IFNAR2与COVID-19住院显著相关,P = 9.8 × 10-11
- IL-10RB与COVID-19住院显著相关,P = 2.3 × 10-14
- 三个蛋白的cis-eQTL遗传工具与COVID-19住院有强共定位证据
关键数值与推荐
- 以顺式表达数量性状位点(cis-eQTL)作为遗传工具进行孟德尔随机化
- 通过全表型关联扫描与通路富集分析区分IL10RB与IFNAR2的共享eQTL信号
临床怎么用
- 为靶向IFNAR2和ACE2的药物开展COVID-19早期治疗临床试验提供优先依据
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2, P = 1.6 × 10-6; IFNAR2, P = 9.8 × 10-11 and IL-10RB, P = 2.3 × 10-14) using cis-expression quantitative trait loci genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared expression quantitative trait loci signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.
引用
- Gaziano L, Giambartolomei C, Pereira AC, et al. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med. 2021. PMID: 33837377. doi:10.1038/s41591-021-01310-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。